KFI conducts feline Target Animal Safety study for Solensia® (frunevetmab).

Solensia® is the first feline injectable mAB designed specifically for cats suffering from pain associated with osteoarthritis. The European Commission granted Zoetis Inc. the marketing authorization on Feb. 22, 2021. This once monthly feline injectable targets and neutralizes Nerve Growth Factor using a monoclonal antibody, resulting in a reduction in pain.

Zoetis Inc. – Zoetis Receives European Commission Marketing Authorization for Solensia®(frunevetmab), a New Therapy for Feline Osteoarthritis Pain